Heart transplant trial tests safer infection prevention
NCT ID NCT07079735
Summary
This study aims to find the best drug to prevent a common and serious viral infection (CMV) in people who have received a heart transplant. It will compare the safety and effectiveness of a newer drug, letermovir, against the current standard, valganciclovir, in 150 adult transplant patients. The main goal is to see if the newer drug works just as well while causing fewer side effects related to low white blood cell counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV VIREMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University/NYP Milstein Hospital
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NYP-Weill Cornell
RECRUITINGNew York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.